Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/22321| Title: | Occult Gastrointestinal Perforation in a Patient With EGFR-Mutant Non-Small-Cell Lung Cancer Receiving Combination Chemotherapy With Atezolizumab and Bevacizumab: Brief Report. | Austin Authors: | Gunjur, Ashray ;Chong, Geoffrey ;Lim, Adeline ;Lau, Eddie ;Mitchell, Paul L R ;John, Thomas ;Arulananda, Surein | Affiliation: | School of Cancer Medicine, La Trobe University, Heidelberg, Australia Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, Victoria, Australia Cancer Immuno-Biology Laboratory, Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia Department of Radiology, Austin Health, Heidelberg, Victoria, Australia Department of Radiation Oncology, Austin Health, Heidelberg, Victoria, Australia Department of Medical Oncology, Austin Health, Heidelberg, Victoria, Australia |
Issue Date: | Mar-2020 | Date: | 2019-11-29 | Publication information: | Clinical Lung Cancer 2020; 21(2): e57-e60 | URI: | https://ahro.austin.org.au/austinjspui/handle/1/22321 | DOI: | 10.1016/j.cllc.2019.11.014 | ORCID: | 0000-0001-9713-1872 | Journal: | Clinical lung cancer | PubMed URL: | 31864906 | Type: | Journal Article | Subjects: | Bevacizumab EGFR-mutant Gastro-oesophageal perforation NSCLC SABR |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.